Atlas Trials

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Clinical trial NCT06155383 · RECRUITING

Trial details

NCT number
NCT06155383
Sponsor
RemeGen Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric CancerGastroesophageal Junction Adenocarcinoma
Start date
2023-11-27
Primary completion
2025-01-31
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.